Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Roche pursues European market approval of Herceptin for early-stage HER2-positive breast cancer
March 23rd, 2006
Roche announced the submission of a marketing authorization application to the European Medicines Agency (EMEA) for Herceptin (trastuzumab) as adjuvant treatment for early-stage HER2-positive breast cancer. The application is based on data from the international HERA (HERceptin Adjuvant) study, which showed that Herceptin following standard chemotherapy significantly reduces the risk of cancer coming back, by an outstanding 46%. HER2-positive breast cancer, which affects approximately 20 - 30% of women with breast cancer,2 demands special and immediate attention because HER2-positive tumours are fast growing. Results from four large trials, with...
Source: Women's Health Weekly (2006-03-23)
|
